Dacomitinib in Combination with chemotherapy is effective in lung adenocarcinoma with rare EGFR L747P mutation and bone metastases: a case report - Scorecard - MDSpire
Advertisement
Dacomitinib in Combination with chemotherapy is effective in lung adenocarcinoma with rare EGFR L747P mutation and bone metastases: a case report
Clinical Scorecard: Efficacy of Dacomitinib Combined with Chemotherapy in Treating Lung Adenocarcinoma with the Rare EGFR L747P Mutation and Bone Metastases: A Case Study
At a Glance
Category
Detail
Condition
Lung Adenocarcinoma with EGFR L747P Mutation and Bone Metastases
Key Mechanisms
Dacomitinib is an EGFR tyrosine kinase inhibitor that targets specific mutations.
Target Population
Patients with lung adenocarcinoma harboring the rare EGFR L747P mutation.
Care Setting
Oncology outpatient and inpatient settings.
Key Highlights
Dacomitinib combined with chemotherapy resulted in a partial response in a patient with EGFR L747P mutation.
The patient achieved a progression-free survival (PFS) of 16 months.
Manageable adverse events included skin rash and paronychia.
Guideline-Based Recommendations
Diagnosis
Next-generation sequencing (NGS) is recommended for identifying rare EGFR mutations.
Management
Consider dacomitinib in combination with chemotherapy for patients with EGFR L747P mutation.
Monitoring & Follow-up
Regular monitoring of tumor markers and imaging studies to assess treatment response.
Risks
Monitor for potential adverse effects such as skin rash and paronychia.
Patient & Prescribing Data
56-year-old female with stage IVB lung adenocarcinoma and bone metastases.
Initial chemotherapy with pemetrexed and carboplatin was ineffective; dacomitinib was added leading to improved outcomes.
Clinical Best Practices
Utilize molecular profiling to guide targeted therapy in lung adenocarcinoma.
Combine targeted therapy with chemotherapy for enhanced efficacy in rare EGFR mutations.
